ISSN Online: 3007-1941 ISSN Print: 3007-1933 https://msra.online/index.php/Journal/about

Multidisciplinary Surgical Research Annals
https://msra.online/index.php/Journal/about
Volume 4, Issue 1 (2026)

Blue Pharmacy: Marine Biodiversity as a Sustainable Source of Novel Therapeutics

Samiyah Tasleem*[1] , Muhammad Ali Zafar [2] , Asif Inam[3]

Article Details

Keywords: Blue Pharmacy; Marine Natural Products; Marine Microorganisms; Drug Discovery; Marine Biotechnology; Sustainable Pharmaceuticals

Samiyah Tasleem*
Hafiz Muhammad Ilyas Institute of Pharmacology and Herbal Sciences, (HMIIP&HS) &Department of Applied Sciences, Hamdard University, Karachi, 74800, Pakistan

Muhammad Ali Zafar
Orion Maritime 16-C 3rd Floor 21st East Street, D.H.A. Phase 1 Karachi, 75500, Pakistan

Asif Inam
Bahria School of Maritime and Applied Sciences, Bahria University, Karachi, 75000, Pakistan Email: samiyahtasleem2005@yahoo.com

ABSTRACT

Blue pharmacy represents a rapidly expanding frontier in drug discovery, emphasizing the exploration of marine biodiversity for novel bioactive compounds with pharmaceutical relevance. Marine ecosystems harbor unparalleled biological and chemical diversity, shaped by extreme environmental pressures that drive the evolution of unique secondary metabolites. Marine microorganisms, algae, invertebrates, and their symbiotic associations have emerged as prolific producers of structurally diverse compounds exhibiting anticancer, antimicrobial, antiviral, anti-inflammatory, and neuroprotective activities. Marine microorganisms are increasingly recognized as major producers of bioactive metabolites, offering scalable and renewable drug leads. Advances in omics technologies, genome mining, and synthetic biology have significantly accelerated the identification and characterization of marine natural products, overcoming traditional cultivation and supply limitations. Several marine-derived compounds have successfully transitioned into clinical use, including anticancer and analgesic drugs, highlighting the translational potential of blue pharmacy. However, challenges related to sustainable harvesting, ecological conservation, and regulatory pathways remain critical considerations. This review synthesizes recent developments in marine-derived drug discovery, therapeutic applications, sustainability strategies, and alignment with global health and Sustainable Development Goals (SDGs). Blue pharmacy is positioned as a key contributor to future pharmaceutical innovation, addressing antimicrobial resistance, chronic diseases, and unmet medical needs through environmentally responsible approaches.

INTRODUCTION:

Marine Biodiversity as a Reservoir of Chemical Innovation

The marine environment covers more than 70% of the Earth's surface and contains the majority of global biodiversity. Oceans encompass a wide spectrum of ecosystems, including coral reefs, mangroves, deep-sea trenches, hydrothermal vents, polar seas, and hypersaline lagoons. These habitats are characterized by highly variable and often extreme physicochemical conditions, such as elevated hydrostatic pressure, fluctuating salinity, limited nutrient availability, reduced light penetration, and pronounced temperature gradients. Unlike terrestrial ecosystems, marine environments impose strong selective pressures that drive the evolution of specialized physiological and biochemical adaptations (Blunt et al., 2018; Carroll et al., 2021).

These environmental constraints have resulted in the development of unique metabolic pathways among marine organisms, leading to the biosynthesis of structurally diverse and chemically novel secondary metabolites. Many of these compounds exhibit features rarely observed in terrestrial natural products, including extensive halogenation, unusual amino acid residues, macrocyclic scaffolds, and complex polyketide–peptide hybrids. Such structural novelty is often associated with potent and selective biological activities, making marine natural products particularly attractive as pharmaceutical lead compounds (Mayer et al., 2010; Leal et al., 2020).

Marine Organisms and Bioactive Metabolite Production

Marine microorganisms—including bacteria, fungi, cyanobacteria, and microalgae—are increasingly recognized as major producers of bioactive metabolites, contributing significantly to the growing repertoire of marine natural products (Romano et al., 2019; Leal et al., 2020). These microorganisms often form symbiotic associations with marine invertebrates such as sponges, tunicates, corals, and mollusks, where they play a key role in the biosynthesis of pharmacologically active compounds (Carroll et al., 2021). Large-scale surveys of marine natural products have documented thousands of novel compounds with demonstrated anticancer, antimicrobial, antiviral, anti-inflammatory, neuroprotective, and enzyme-inhibitory activities (Blunt et al., 2018; Carroll et al., 2021).

Several marine-derived compounds have successfully transitioned from discovery to clinical application, underscoring the translational potential of marine biodiversity. Examples include trabectedin, approved for the treatment of soft-tissue sarcoma and ovarian cancer, and ziconotide, a peptide analgesic derived from cone snail venom used for severe chronic pain management (Mayer et al., 2010). These success stories highlight the importance of continued exploration of marine ecosystems for pharmaceutical innovation.

Concept and Scope of Blue Pharmacy

The concept of blue pharmacy integrates marine biotechnology, pharmacology, and sustainability to systematically translate marine natural products into therapeutic agents. Beyond compound discovery, blue pharmacy emphasizes environmentally responsible bioprospecting, sustainable supply strategies, and scalable production methods. This approach aligns pharmaceutical development with marine conservation and global sustainability goals (Leal et al., 2021).

Recent advances in genome mining, metabolomics, synthetic biology, and microbial fermentation have further strengthened the blue pharmacy framework. These technologies enable the identification of cryptic biosynthetic gene clusters and the sustainable production of bioactive compounds without extensive harvesting of marine organisms (Ziemert et al., 2016; Trindade et al., 2021). By combining the unparalleled chemical diversity of marine life with modern biotechnological tools, blue pharmacy represents a forward-looking strategy for expanding the pharmaceutical pipeline while preserving marine ecosystems.

Marine Sources of Bioactive Compounds

Marine ecosystems represent one of the most prolific reservoirs of chemically diverse natural products. The extraordinary biological diversity of marine organisms, coupled with their exposure to extreme and variable environmental conditions, has driven the evolution of specialized biosynthetic pathways that generate structurally unique secondary metabolites. These compounds exhibit a wide spectrum of biological activities and have become a cornerstone of blue pharmacy–based drug discovery. Among marine sources, microorganisms, algae, and invertebrates—often in close association with symbiotic microbes—play a dominant role in the production of pharmacologically relevant molecules.

Marine Microorganisms

Marine microorganisms, including bacteria, fungi, cyanobacteria, and actinomycetes, are now widely recognized as major producers of bioactive secondary metabolites with significant pharmaceutical potential. Unlike terrestrial microbes, marine microorganisms inhabit environments characterized by high pressure, salinity stress, nutrient limitation, and chemical competition, which collectively drive the evolution of novel metabolic pathways and chemical scaffolds (Romano et al., 2019; Leal et al., 2020).

Marine actinomycetes, particularly genera such as Salinispora, Streptomyces, and Micromonospora, have been identified as prolific sources of polyketides, nonribosomal peptides, and hybrid compounds with potent anticancer, antibacterial, and proteasome-inhibitory activities (Fenical & Jensen, 2006; Carroll et al., 2021). Notably, salinosporamide A, derived from Salinispora tropica, represents one of the most prominent examples of a marine microbial metabolite that advanced into clinical evaluation for cancer therapy.

Marine fungi have also gained increasing attention as a rich and underexplored source of bioactive compounds. Marine-derived fungal species produce alkaloids, terpenoids, peptides, and xanthones with antimicrobial, cytotoxic, antioxidant, and enzyme-inhibitory properties (Pan et al., 2024; Shi et al., 2024). Advances in cultivation strategies, epigenetic modulation, and co-culture techniques have significantly expanded the chemical diversity accessible from marine fungi by activating otherwise silent biosynthetic gene clusters (Romano et al., 2019; Ziemert et al., 2016).

Recent developments in genome mining and metagenomics have further transformed marine microbial drug discovery. Whole-genome sequencing has revealed that many marine microorganisms possess far more biosynthetic gene clusters than the number of compounds they are observed to produce under laboratory conditions, suggesting vast untapped chemical potential (Ziemert et al., 2016; Trindade et al., 2021). As a result, marine microorganisms are increasingly viewed as renewable and scalable sources of pharmaceutical leads within the blue pharmacy framework.

Marine Algae (Seaweeds and Microalgae)

Marine algae, encompassing both macroalgae (seaweeds) and microalgae, constitute another important source of bioactive compounds with pharmaceutical and nutraceutical applications. Marine algae are taxonomically diverse and are broadly classified into green (Chlorophyta), brown (Phaeophyceae), and red (Rhodophyta) algae, each producing distinct classes of secondary metabolites shaped by their ecological roles and environmental pressures.

Macroalgae are particularly rich in sulfated polysaccharides such as fucoidan, carrageenan, ulvan, and agarans, which exhibit a wide range of biological activities including antioxidant, antiviral, anticoagulant, anti-inflammatory, and immunomodulatory effects (Pangestuti & Kim, 2020; Shannon & Abu-Ghannam, 2019). Fucoidan, a sulfated polysaccharide predominantly found in brown algae, has demonstrated promising anticancer and immune-enhancing properties, attracting significant interest for pharmaceutical development.

In addition to polysaccharides, marine algae produce phenolic compounds, phlorotannins, carotenoids (e.g., fucoxanthin, astaxanthin), polyunsaturated fatty acids, and sterols with antioxidant, neuroprotective, and cardioprotective activities (Holdt & Kraan, 2011; Pangestuti & Kim, 2020). These compounds play essential ecological roles in UV protection, herbivore deterrence, and oxidative stress management, which directly translate into therapeutic relevance.

Microalgae and cyanobacteria are also recognized as prolific producers of bioactive metabolites, including peptides, alkaloids, and polyketides. Cyanobacterial compounds such as dolastatins, apratoxins, and curacins exhibit potent cytotoxicity against cancer cells and have inspired several synthetic and semi-synthetic drug candidates (Gerwick & Moore, 2012; Carroll et al., 2021). The rapid growth rates and amenability of microalgae to controlled cultivation further enhance their value as sustainable sources of bioactive compounds within blue pharmacy initiatives.

Marine Invertebrates and Symbiotic Microorganisms

Marine invertebrates, including sponges, tunicates, mollusks, bryozoans, and corals, have historically been among the most intensively studied marine sources of bioactive natural products. These organisms are often sessile or slow-moving and rely heavily on chemical defense mechanisms to deter predators, prevent fouling, and compete for space, leading to the production of highly potent secondary metabolites (Mehbub et al., 2014; Carroll et al., 2021).

Marine sponges are particularly renowned for their chemical diversity, producing alkaloids, terpenes, peptides, and macrolides with antimicrobial, anticancer, antiviral, and anti-inflammatory activities. However, it is now well established that many sponge-derived compounds are biosynthesized by associated microbial symbionts rather than the sponge host itself (Mehbub et al., 2014; Taylor et al., 2007). This realization has reshaped marine drug discovery by highlighting the critical role of host–microbe interactions in natural product biosynthesis.

Tunicates have yielded clinically significant compounds such as trabectedin and plitidepsin, both of which originated from symbiotic microbial pathways and are now approved or in advanced clinical use for cancer and viral diseases (Mayer et al., 2010; Carroll et al., 2021). Similarly, mollusks such as cone snails produce neurotoxic peptides (conotoxins) with exceptional specificity for ion channels and receptors, leading to the development of ziconotide for pain management.

The recognition that symbiotic microorganisms are responsible for the biosynthesis of many invertebrate-derived metabolites has shifted research efforts toward microbial isolation, genome analysis, and heterologous expression. This shift aligns strongly with the principles of blue pharmacy, enabling sustainable production while minimizing ecological disturbance to marine ecosystems (Leal et al., 2021).



Therapeutic Applications of Blue Pharmacy

Marine-derived natural products have demonstrated broad therapeutic relevance, positioning blue pharmacy as a major contributor to modern drug discovery. The unique chemical scaffolds generated by marine organisms often interact with biological targets in ways distinct from terrestrial compounds, resulting in high potency and selectivity. Several marine natural products have progressed into clinical use, while many others remain in advanced preclinical or clinical development stages. The most prominent therapeutic applications include anticancer, antimicrobial, antiviral, neuroactive, and anti-inflammatory indications.

Anticancer Applications

Cancer remains one of the leading global causes of mortality, driving the continuous search for novel chemotherapeutic agents. Marine natural products have emerged as an important source of anticancer compounds due to their ability to interfere with cell division, DNA replication, and signal transduction pathways. Many marine-derived metabolites exhibit strong antiproliferative and pro-apoptotic effects, often at nanomolar concentrations (Blunt et al., 2024; Zhang et al., 2024).

Trabectedin, originally isolated from the marine tunicate Ecteinascidia turbinata, is a landmark example of a marine-derived anticancer drug. It binds to the minor groove of DNA, disrupting transcription-coupled nucleotide excision repair, and is approved for the treatment of soft-tissue sarcoma and ovarian cancer (Mayer et al., 2010; Carroll et al., 2021). Bryostatin-1, derived from the bryozoan Bugula neritina, modulates protein kinase C (PKC) activity and has been extensively investigated for anticancer and immunomodulatory effects, although its clinical development has been challenged by supply and toxicity issues (Newman & Cragg, 2020). Additionally, marine microorganisms have yielded numerous cytotoxic compounds, including salinosporamides, didemnins, and apratoxins, which target proteasomes, translation machinery, and growth factor signaling pathways (Gerwick & Moore, 2012; Shi et al., 2024). These findings underscore the importance of marine ecosystems as a reservoir for novel anticancer chemotypes.

3.2. Antimicrobial and Anti-Infective Applications

The rapid emergence of antimicrobial resistance (AMR) represents a critical global health challenge. Marine natural products offer a promising avenue for discovering new antimicrobial agents with novel mechanisms of action. Marine microorganisms, particularly actinomycetes and fungi, produce antibiotics that differ structurally and functionally from conventional terrestrial antibiotics (Leal et al., 2020; Pan et al., 2024).

Salinosporamide A, derived from Salinispora tropica, exhibits potent antibacterial and proteasome-inhibitory activity and has been explored for both anticancer and anti-infective applications. Marine-derived peptides, alkaloids, and halogenated compounds have shown efficacy against multidrug-resistant pathogens, including Staphylococcus aureus, Pseudomonas aeruginosa, and Candida species (Romano et al., 2019; Shi et al., 2024). Furthermore, sulfated polysaccharides from marine algae display broad-spectrum antimicrobial activity by disrupting microbial adhesion, biofilm formation, and cell membrane integrity (Shannon & Abu-Ghannam, 2019). These properties position marine compounds as promising candidates for next-generation anti-infective therapies.

Antiviral Applications

Marine natural products have gained increased attention for their antiviral potential, particularly following global viral outbreaks. Several marine-derived compounds inhibit viral attachment, entry, replication, or assembly. Sulfated polysaccharides such as fucoidan and carrageenan exhibit strong antiviral activity against enveloped viruses, including influenza viruses, herpes simplex virus, and coronaviruses, by blocking viral adsorption and entry (Pangestuti & Kim, 2020; Fitton et al., 2021).

Marine peptides and alkaloids have also demonstrated inhibitory activity against viral proteases and polymerases, highlighting their potential as antiviral drug leads (Zhang et al., 2024). The structural complexity and charge density of marine polysaccharides contribute to their broad-spectrum antiviral efficacy and favorable safety profiles, making them attractive candidates for therapeutic development.

Neuroactive and Pain Management Applications

Marine ecosystems have yielded some of the most potent neuroactive compounds known to science. Ziconotide, a synthetic version of a peptide isolated from the venom of the cone snail Conus magus, is an FDA-approved analgesic used for the management of severe chronic pain. It acts by selectively blocking N-type calcium channels, thereby inhibiting neurotransmitter release in pain pathways (Mayer et al., 2010; Newman & Cragg, 2020).

Beyond pain management, marine peptides and alkaloids show promise for neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease. These compounds exhibit neuroprotective, anti-inflammatory, and synaptic-modulating effects, often targeting ion channels, receptors, and enzymes involved in neurodegeneration (Carroll et al., 2021; Zhang et al., 2024). The high specificity of marine neurotoxins offers unique opportunities for developing targeted neurological therapies.

Anti-Inflammatory and Immunomodulatory Applications

Chronic inflammation underlies numerous diseases, including arthritis, cardiovascular disorders, and metabolic syndromes. Marine natural products, particularly algal polysaccharides and lipid-derived metabolites, display significant anti-inflammatory and immunomodulatory effects. Fucoidan has been extensively studied for its ability to inhibit pro-inflammatory cytokines, modulate immune cell activity, and reduce oxidative stress (Pangestuti & Kim, 2020; Fitton et al., 2021).

Marine sterols, fatty acids, and peptides further contribute to inflammation control by regulating inflammatory signaling pathways such as NF-κB and MAPK (Holdt & Kraan, 2011). These properties reinforce the therapeutic relevance of blue pharmacy beyond oncology and infectious diseases.

Therapeutic Area	Representative Marine Compounds	Biological Activity
Cancer	Trabectedin, Bryostatin-1	Antiproliferative
Infectious diseases	Salinosporamide A	Antibacterial
Pain management	Ziconotide	Analgesic
Inflammation	Fucoidan	Anti-inflammatory
Neurodegeneration	Marine peptides	Neuroprotective

Major Marine Sources and Classes of Bioactive Compounds

Marine Source	Compound Classes	Representative Examples	Therapeutic Relevance
Marine bacteria & actinomycetes	Polyketides, peptides, alkaloids	Salinosporamide A	Anticancer, antimicrobial
Marine fungi	Terpenoids, xanthones, peptides	Aspergillic compounds	Antibacterial, anticancer
Macroalgae (seaweeds)	Polysaccharides, phenolics	Fucoidan, carrageenan	Anti-inflammatory, antiviral
Microalgae & cyanobacteria	Peptides, alkaloids	Dolastatins	Anticancer
Marine invertebrates	Alkaloids, macrolides,	Trabectedin, ziconotide	Cancer, pain

Marine Source	Compound Classes	Representative Examples	Therapeutic Relevance
	peptides		management



Figure 2. Marine sources of bioactive compounds within the blue pharmacy framework

Schematic overview of the principal marine biological sources of pharmacologically active compounds, including marine microorganisms (bacteria, fungi, and actinomycetes), macroalgae and microalgae, and marine invertebrates with their associated microbial symbionts The figure highlights the major classes of secondary metabolites produced by each source—such as polyketides, peptides, alkaloids, polysaccharides, and terpenoids—and maps their established and emerging therapeutic applications, including anticancer, antimicrobial, antiviral, anti-inflammatory, neuroactive, and immunomodulatory activities. This framework illustrates the integrative role of marine biodiversity in blue pharmacy–driven drug discovery.



Figure 3. Mechanisms of action of selected marine-derived bioactive compounds
Illustration of the principal molecular and cellular mechanisms underlying the therapeutic effects of representative marine natural products. Antiproliferative mechanisms include DNA binding, proteasome inhibition, and disruption of cell cycle regulation; antimicrobial mechanisms involve membrane disruption, enzyme inhibition, and biofilm interference; antiviral effects include inhibition of viral attachment, entry, and replication; neuroactive actions target ion channels, neurotransmitter release, and synaptic signaling; and anti-inflammatory effects involve modulation of cytokine production, oxidative stress pathways, and key inflammatory signaling cascades such as NF-κB and MAPK. Together, these mechanisms demonstrate the multi-target therapeutic potential of marine-derived compounds in blue pharmacy.

Technological Advances Supporting Blue Pharmacy

The successful translation of marine natural products into therapeutic agents has historically been constrained by challenges such as low compound yields, complex chemical structures, supply limitations, and difficulties in cultivating marine organisms. However, rapid advances in analytical, computational, and biotechnological tools have transformed blue pharmacy into a data-driven and sustainable drug discovery paradigm. Modern technologies—including genome mining, metabolomics, artificial intelligence (AI)–assisted drug discovery, and synthetic biology—now enable the systematic identification, characterization, and scalable production of marine bioactive metabolites (Ziemert et al., 2016; Trindade et al., 2021).

Genome Mining and Metagenomics

Genome mining has revolutionized marine natural product discovery by enabling the identification of biosynthetic gene clusters (BGCs) responsible for secondary metabolite production. Advances in next-generation sequencing (NGS) have revealed that marine microorganisms harbor a far greater biosynthetic potential than previously recognized, with many BGCs remaining transcriptionally silent under standard laboratory conditions (Ziemert et al., 2016; Carroll et al., 2021).

Bioinformatic platforms such as antiSMASH, PRISM, and MIBiG allow researchers to predict the chemical classes and biosynthetic logic of natural products directly from genomic data. These tools have proven particularly valuable for marine bacteria, actinomycetes, and fungi, where genome analysis often uncovers dozens of unexpressed BGCs per strain (Trindade et al., 2021). Metagenomic approaches further extend this capability by enabling access to the genetic material of uncultivable marine microorganisms, which constitute the majority of marine microbial diversity.

By coupling genome mining with heterologous expression systems, researchers can activate cryptic gene clusters and produce novel compounds without harvesting marine organisms, aligning strongly with sustainability principles in blue pharmacy (Zhang et al., 2024).

Metabolomics and Advanced Analytical Techniques

Metabolomics plays a central role in characterizing the chemical diversity of marine natural products. High-resolution analytical platforms such as liquid chromatography–mass spectrometry (LC–MS), nuclear magnetic resonance (NMR) spectroscopy, and mass spectrometry imaging (MSI) enable rapid detection, dereplication, and structural elucidation of complex marine metabolites (Leal et al., 2021).

Untargeted metabolomics allows comprehensive profiling of marine extracts, facilitating the identification of novel compounds and the comparison of metabolic profiles under different cultivation or environmental conditions. Molecular networking approaches, such as those implemented in the Global Natural Products Social Molecular Networking (GNPS) platform, have significantly improved the efficiency of marine natural product discovery by clustering structurally related metabolites and reducing redundancy in compound isolation (Wang et al., 2016; Shi et al., 2024).

Furthermore, metabolomics integrated with genomics (metabologenomics) provides direct links between biosynthetic gene clusters and their chemical products, accelerating lead identification and mechanism-of-action studies. These approaches are now considered essential tools in blue pharmacy research pipelines.

Artificial Intelligence and Machine Learning in Marine Drug Discovery

Artificial intelligence (AI) and machine learning (ML) have emerged as transformative tools in pharmaceutical research, including marine drug discovery. AI-driven algorithms can analyze large datasets generated from genomics, metabolomics, and bioassays to predict bioactivity, toxicity, and pharmacokinetic properties of marine-derived compounds (Stokes et al., 2020; Zhang et al., 2024).

In blue pharmacy, AI is increasingly used to prioritize marine natural products for further investigation by predicting therapeutic relevance and identifying molecular targets. Deep learning models can also assist in de novo drug design by generating synthetic analogs of marine compounds with improved drug-like properties while retaining biological activity. These approaches reduce time, cost, and attrition rates associated with traditional drug development.

AI-assisted virtual screening has proven particularly valuable in identifying antiviral, antimicrobial, and anticancer candidates from large marine compound libraries. As marine natural product databases continue to expand, AI is expected to play an increasingly central role in unlocking the therapeutic potential of marine biodiversity (Carroll et al., 2021).

Synthetic Biology and Heterologous Expression

Synthetic biology has addressed one of the most persistent challenges in marine drug discovery: sustainable and scalable production. Many marine-derived compounds occur in trace amounts or are produced by slow-growing or uncultivable organisms. Synthetic biology enables the transfer of biosynthetic gene clusters into fast-growing, genetically tractable hosts such as Escherichia coli, Streptomyces, or yeast, allowing controlled and sustainable production of valuable metabolites (Ziemert et al., 2016; Trindade et al., 2021).

Advances in pathway engineering, promoter optimization, and CRISPR-based genome editing have significantly improved yields of marine natural products and facilitated the generation of novel analogs. These

engineered biosynthetic systems also enable structure–activity relationship (SAR) studies and optimization of pharmacological properties, bridging the gap between natural product discovery and drug development.
Importantly, synthetic biology reduces the need for large-scale harvesting of marine organisms, thereby minimizing ecological impact and supporting conservation-driven blue pharmacy initiatives.

Integrated and Sustainable Discovery Pipelines

The integration of genome mining, metabolomics, AI, and synthetic biology has led to the development of holistic discovery pipelines tailored for blue pharmacy. These pipelines enable rapid progression from environmental sampling to lead identification, biological evaluation, and scalable production. By combining multi-omics data with computational tools, researchers can systematically explore marine chemical space while adhering to sustainability and ethical bioprospecting principles (Leal et al., 2021; Zhang et al., 2024).
Furthermore, these technologies support international frameworks such as the Nagoya Protocol by enabling benefit-sharing and reducing reliance on physical resource extraction. As a result, technological innovation is not only accelerating marine drug discovery but also reshaping it into a more responsible and sustainable enterprise.

Sustainability and Environmental Considerations in Blue Pharmacy

The rapid expansion of marine natural product research has highlighted the urgent need to balance pharmaceutical innovation with marine ecosystem conservation. Oceans face increasing pressures from climate change, pollution, overexploitation, and biodiversity loss, making sustainability a central pillar of blue pharmacy. Sustainable blue pharmacy prioritizes environmentally responsible bioprospecting, non-destructive sampling, cultivation-independent technologies, and scalable production strategies that minimize ecological disturbance while maximizing therapeutic benefit (Leal et al., 2021; UN Ocean Decade, 2021).

Non-Destructive and Ethical Bioprospecting

Traditional marine bioprospecting often relied on large-scale harvesting of invertebrates such as sponges, tunicates, and corals, raising concerns about habitat degradation and species depletion. Sustainable blue pharmacy has shifted toward non-destructive sampling approaches, including small-volume collections, in situ sampling, and the use of remotely operated vehicles (ROVs) to minimize physical damage to sensitive marine habitats (Leal et al., 2021).
Ethical bioprospecting frameworks emphasize compliance with international agreements such as the Convention on Biological Diversity (CBD) and the Nagoya Protocol, which promote access and benefit-sharing with coastal and indigenous communities. These frameworks ensure that marine genetic resources are used responsibly and that scientific and economic benefits are equitably distributed (Harden-Davies et al., 2022). By integrating ethical considerations into research design, blue pharmacy aligns drug discovery with long-term marine stewardship.

Microbial Fermentation as a Sustainable Production Strategy

One of the most significant sustainability advances in blue pharmacy is the shift from organism harvesting to microbial fermentation. Many marine-derived bioactive compounds initially attributed to macro-organisms are now known to be produced by associated microorganisms. Cultivating these microbes in controlled fermentation systems enables continuous production of valuable metabolites without repeated sampling from the marine environment (Taylor et al., 2007; Trindade et al., 2021).
Bioreactor-based fermentation offers several advantages, including scalability, reproducibility, and reduced environmental impact. Fermentation conditions can be optimized to enhance metabolite yield, reduce waste, and lower energy consumption. This approach has been successfully applied to the production of clinically relevant compounds such as trabectedin and salinosporamide analogs, demonstrating the feasibility of

sustainable marine drug supply chains (Newman & Cragg, 2020).

Cultivation-Independent and Omics-Based Approaches

A major challenge in marine microbiology is that a large proportion of marine microorganisms remain uncultivable using conventional techniques. Cultivation-independent approaches, including metagenomics, metatranscriptomics, and single-cell genomics, allow access to the biosynthetic potential of these organisms without the need for isolation or large-scale cultivation (Ziemert et al., 2016; Trindade et al., 2021).

These technologies reduce environmental pressure by minimizing sample collection while maximizing data extraction from small environmental samples. Genome mining and heterologous expression further enable the production of marine metabolites in laboratory hosts, bypassing the need for continuous marine sampling. Such approaches represent a paradigm shift toward conservation-oriented drug discovery within blue pharmacy.

Synthetic Biology and Biosynthetic Engineering

Synthetic biology plays a central role in advancing sustainability in blue pharmacy by enabling the reconstruction and optimization of marine biosynthetic pathways in heterologous hosts. Through pathway refactoring, promoter engineering, and CRISPR-based genome editing, biosynthetic gene clusters can be optimized for high-yield production in industrially relevant microorganisms such as Streptomyces, yeast, or microalgae (Ziemert et al., 2016; Carroll et al., 2021).

Biosynthetic engineering not only improves yield but also allows the generation of novel analogs with enhanced pharmacological properties and reduced toxicity. Importantly, synthetic biology eliminates dependence on rare or slow-growing marine organisms, thereby supporting biodiversity conservation and ecosystem resilience. This approach aligns strongly with green chemistry principles by reducing solvent use, waste generation, and energy consumption during production.

Alignment with Global Sustainability Frameworks

Sustainable blue pharmacy is closely aligned with global environmental and development frameworks, particularly the United Nations Sustainable Development Goals (SDGs). Marine drug discovery contributes directly to SDG 3 (Good Health and Well-Being) by providing new therapeutic agents, while responsible marine resource use supports SDG 14 (Life Below Water) (UN Ocean Decade, 2021).

The United Nations Decade of Ocean Science for Sustainable Development (2021–2030) emphasizes the integration of ocean science, innovation, and policy to achieve sustainable ocean use. Blue pharmacy embodies this vision by combining cutting-edge biotechnology with conservation-driven research strategies. By fostering interdisciplinary collaboration among scientists, policymakers, and industry, blue pharmacy supports long-term ocean health while addressing unmet medical needs.

Climate Change, Resilience, and Future Challenges

Climate change poses both challenges and opportunities for blue pharmacy. Ocean warming, acidification, and deoxygenation threaten marine biodiversity and may alter the distribution and metabolic profiles of marine organisms. At the same time, environmental stress can induce the production of novel secondary metabolites, potentially expanding the chemical diversity available for drug discovery (Leal et al., 2021).

Future sustainable blue pharmacy initiatives must integrate climate resilience into research and production strategies. This includes monitoring ecosystem health, preserving genetic diversity, and developing adaptive biotechnological platforms capable of responding to environmental change. Long-term sustainability will depend on proactive conservation, robust regulatory frameworks, and continued technological innovation.

Toward a Conservation-Driven Drug Discovery Model

The evolution of blue pharmacy reflects a broader transition toward conservation-driven drug discovery, where pharmaceutical innovation and environmental responsibility are mutually reinforcing. By prioritizing non-destructive sampling, microbial fermentation, cultivation-independent technologies, and biosynthetic engineering, blue pharmacy minimizes ecological impact while maximizing therapeutic output (Leal et al., 2021).

This integrated approach ensures that marine ecosystems remain viable sources of biomedical innovation for future generations. As technological capabilities continue to advance, sustainable blue pharmacy will play a pivotal role in shaping a responsible and resilient pharmaceutical pipeline grounded in marine biodiversity.

6. Blue Pharmacy and the United Nations Sustainable Development Goals (SDGs)

The concept of blue pharmacy extends beyond pharmaceutical innovation by directly contributing to global sustainability agendas, particularly the United Nations Sustainable Development Goals (SDGs). By integrating marine biodiversity conservation, advanced biotechnology, and responsible production systems, blue pharmacy offers a model in which human health advancement and environmental stewardship are mutually reinforcing. Among the 17 SDGs, blue pharmacy has particularly strong and measurable impacts on SDG 3 (Good Health and Well-Being), SDG 9 (Industry, Innovation, and Infrastructure), SDG 12 (Responsible Consumption and Production), and SDG 14 (Life Below Water) (UN Ocean Decade, 2021).

Contribution to SDG 3: Good Health and Well-Being

SDG 3 aims to ensure healthy lives and promote well-being for all ages. Blue pharmacy contributes directly to this goal through the discovery and development of novel therapeutics derived from marine natural products. Marine organisms produce chemically diverse compounds with unique mechanisms of action that address unmet medical needs, particularly in oncology, infectious diseases, inflammation, pain management, and neurodegenerative disorders (Mayer et al., 2010; Carroll et al., 2021).

Marine-derived drugs such as trabectedin, ziconotide, and plitidepsin demonstrate how marine biodiversity can be translated into clinically effective medicines. Moreover, marine polysaccharides and peptides are increasingly investigated for antiviral and immunomodulatory properties, supporting preparedness against emerging infectious diseases (Fitton et al., 2021; Pangestuti & Kim, 2020). By expanding the pharmaceutical pipeline with structurally novel compounds, blue pharmacy strengthens global health resilience and therapeutic diversity, which are central objectives of SDG 3.

Contribution to SDG 9: Industry, Innovation, and Infrastructure

SDG 9 emphasizes the importance of fostering innovation, building resilient infrastructure, and promoting sustainable industrialization. Blue pharmacy is inherently innovation-driven, relying on cutting-edge technologies such as genome mining, metabolomics, artificial intelligence (AI), and synthetic biology to unlock the therapeutic potential of marine ecosystems (Ziemert et al., 2016; Trindade et al., 2021).

The integration of multi-omics platforms and computational tools has enabled more efficient and cost-effective marine drug discovery pipelines. These technological advances support the development of high-value biotechnological industries, including marine biotechnology startups, pharmaceutical manufacturing, and bioinformatics enterprises. By stimulating research and development in marine-derived therapeutics, blue pharmacy contributes to knowledge-based economic growth and strengthens scientific infrastructure, particularly in coastal and developing regions rich in marine biodiversity (Leal et al., 2021).

Contribution to SDG 12: Responsible Consumption and Production

SDG 12 focuses on ensuring sustainable consumption and production patterns, a critical concern in pharmaceutical development. Traditional drug discovery approaches have often relied on resource-intensive extraction methods with significant environmental footprints. In contrast, blue pharmacy prioritizes responsible production through microbial fermentation, biosynthetic engineering, and cultivation-independent technologies that reduce reliance on natural harvesting (Newman & Cragg, 2020).

Bioreactor-based production systems enable scalable and reproducible synthesis of marine-derived compounds while minimizing waste, energy use, and ecological disturbance. Synthetic biology further enhances sustainability by allowing the design of optimized biosynthetic pathways that increase yield and reduce the need for hazardous solvents or chemical reagents. These approaches align with green chemistry principles and promote circular bioeconomy models, reinforcing the objectives of SDG 12 (Leal et al., 2021).

Contribution to SDG 14: Life Below Water

SDG 14 aims to conserve and sustainably use oceans, seas, and marine resources. Blue pharmacy supports this goal by shifting marine drug discovery away from extractive practices toward conservation-oriented research strategies. Non-destructive sampling, metagenomics, and heterologous expression reduce pressure on vulnerable marine species and habitats while preserving biodiversity for future generations (Trindade et al., 2021).

Furthermore, blue pharmacy research often generates valuable ecological and biological data that contribute to marine monitoring and conservation efforts. By demonstrating the tangible societal value of healthy marine ecosystems, blue pharmacy provides a strong economic and ethical incentive for ocean protection. This aligns closely with the objectives of the United Nations Decade of Ocean Science for Sustainable Development (2021–2030), which calls for science-based solutions to ensure sustainable ocean use (UN Ocean Decade, 2021).

Synergistic Impacts Across Multiple SDGs

While SDGs 3, 9, 12, and 14 are most directly impacted, blue pharmacy also contributes indirectly to other goals. Capacity building in marine biotechnology supports SDG 4 (Quality Education), while equitable benefit-sharing frameworks align with SDG 10 (Reduced Inequalities). Additionally, climate-resilient research strategies contribute to SDG 13 (Climate Action) by promoting adaptive responses to ocean change (Harden-Davies et al., 2022).

These synergistic impacts highlight blue pharmacy as a cross-cutting solution that bridges health, innovation, sustainability, and environmental conservation. The interdisciplinary nature of blue pharmacy fosters collaboration among scientists, policymakers, industry stakeholders, and local communities, reinforcing integrated development pathways.

Policy Integration and Future Outlook

The success alignment of blue pharmacy with the SDGs calls for supportive coverage frameworks, worldwide collaboration, and sustained funding in marine technological know-how. Regulatory mechanisms that promote moral bioprospecting, records sharing, and benefit-sharing are critical to ensure lengthy-time period sustainability and social recognition. As international call for novel therapeutics continues to upward thrust, blue pharmacy gives a pathway to satisfy healthcare needs without compromising marine atmosphere integrity. looking in advance, the integration of SDG-orientated metrics into marine drug discovery projects could be vital for measuring effect and guiding choice-making. via embedding sustainability signs into studies and development pipelines, blue pharmacy can function a model for responsible innovation inside the life sciences.

Table 2. Alignment of Blue Pharmacy with Key Sustainable Development Goals

SDG	**Contribution of Blue Pharmacy**
SDG 3	Discovery and development of novel marine-derived therapeutics
SDG 9	Advancement of marine biotechnology and innovation-driven industries
SDG 12	Sustainable and responsible production of pharmaceuticals

SDG	Contribution of Blue Pharmacy
SDG 14	Conservation and sustainable use of marine biodiversity

Challenges, Limitations, and Future Perspectives in Blue Pharmacy

Notwithstanding great development in marine natural product research, blue pharmacy faces several medical, technical, regulatory, and moral challenges that should be addressed to ensure its lengthy-term fulfillment and sustainability. information those boundaries is essential for guiding future research strategies and translating marine-derived compounds into clinically authorized therapeutics even as safeguarding marine ecosystems.

Scientific and Technical Challenges

One of the primary demanding situations in blue pharmacy is the inherent complexity of marine natural products. Many marine-derived compounds possess tricky chemical systems, stereochemical complexity, and unusual functional businesses that complicate isolation, structural elucidation, and chemical synthesis (Carroll et al., 2021; Blunt et al., 2024). these factors frequently result in low yields and high production charges, that can restrict preclinical improvement and scientific translation. additionally, the reproducibility of bioactive compound production remains a sizeable problem. Environmental factors inclusive of temperature, salinity, nutrient availability, and microbial network composition can have an effect on metabolite profiles, leading to variability in compound yield and pastime. even though omics-based totally and artificial biology techniques have mitigated a number of these demanding situations, full pathway characterization and solid expression systems are still required for many marine metabolites (Ziemert et al., 2016; Trindade et al., 2021).

Cultivation and Supply Limitations

A large percentage of marine microorganisms continue to be uncultivable beneath standard laboratory conditions, limiting direct get right of entry to to their biosynthetic ability. while metagenomics and heterologous expression have opened new avenues, useful expression of large and complex biosynthetic gene clusters remains technically worrying (Leal et al., 2021). supply constraints have historically impeded the improvement of several promising marine compounds. Early marine drug discovery efforts relied heavily on wild harvesting of invertebrates, raising ecological and scalability concerns. despite the fact that fermentation and biosynthetic engineering now offer sustainable alternatives, organising business-scale manufacturing remains costly and time-extensive (Newman & Cragg, 2020).

Regulatory and Translational Barriers

The translation of marine herbal merchandise into accredited tablets is concern to stringent regulatory requirements. The pharmaceutical development pipeline—from discovery and preclinical testing to scientific trials and regulatory approval—is prolonged, pricey, and related to excessive attrition prices. Marine-derived compounds face additional scrutiny due to their structural novelty and capability toxicity, necessitating widespread protection and pharmacokinetic evaluation (Mayer et al., 2010). furthermore, regulatory frameworks governing get admission to marine genetic sources vary across jurisdictions, complicating international studies collaboration. Compliance with the conference on organic range (CBD) and the Nagoya Protocol calls for clear agreements on get admission to and advantage-sharing, that may put off studies and development if no longer cautiously controlled (Harden-Davies et al., 2022).

Environmental and Climate-Related Constraints

Climate change poses each risk and uncertainties for blue pharmacy. Ocean warming, acidification, deoxygenation, and habitat degradation threaten marine biodiversity and may result in the lack of species earlier than their pharmaceutical capability is explored. modifications in environmental conditions can also modify metabolic pathways, affecting the availability and consistency of bioactive compounds (Leal et al., 2021). at the identical time, weather-driven pressure responses can also set off the manufacturing of novel metabolites, imparting each a mission and an opportunity for destiny research. Integrating weather resilience into marine drug discovery strategies can be vital to making sure lengthy-term sustainability.

7.5. Ethical, Legal, and Social Considerations

Ethical considerations are increasingly more valuable to blue pharmacy research. accountable bioprospecting requires transparency, equitable benefit-sharing, and recognize for the rights of coastal and indigenous communities. Failure to cope with those troubles risks undermining public consider and global cooperation (Harden-Davies et al., 2022). records possession, intellectual belongings rights, and commercialization pathways must also be cautiously controlled to balance innovation incentives with international fairness. As marine biotechnology advances, aligning ethical frameworks with medical development will stay a crucial precedence.

Future Perspectives and Research Directions

The future of blue pharmacy lies inside the integration of advanced technologies, interdisciplinary collaboration, and sustainability-pushed innovation. synthetic intelligence and system getting to know are predicted to play an increasing number of essential roles in predicting bioactivity, optimizing lead compounds, and lowering attrition in drug development pipelines (Stokes et al., 2020). synthetic biology and metabolic engineering will in addition decorate sustainable production via enabling absolutely synthetic or semi-synthetic manufacturing routes for complex marine compounds. Coupling those strategies with green chemistry principles will reduce environmental footprints and improve monetary feasibility. moreover, worldwide initiatives inclusive of the United Nations Decade of Ocean science for Sustainable development (2021–2030) offer a strategic framework for aligning marine drug discovery with conservation and policy objectives (UN Ocean Decade, 2021). future blue pharmacy efforts have to prioritize ability building, information sharing, and global collaboration to make certain equitable and sustainable get admission to marine genetic assets.

Toward a Sustainable and Resilient Blue Pharmacy

In precis, whilst blue pharmacy faces big challenges related to complexity, supply, regulation, and environmental change, ongoing technological and policy advances provide possible answers. through embracing incorporated, conservation-orientated procedures, blue pharmacy can evolve right into a resilient and ethically grounded model of pharmaceutical innovation. endured investment in research, infrastructure, and international cooperation can be vital to figuring out the overall capability of marine biodiversity for human health and sustainable development.

Conclusion

Blue pharmacy represents a transformative paradigm in pharmaceutical research by means of strategically harnessing the sizeable and largely untapped chemical variety of marine biodiversity in a responsible and sustainable manner. Marine ecosystems, which embody the general public of Earth’s organic variety, have developed under excessive and noticeably variable environmental conditions, giving upward push to structurally particular and biologically mighty natural merchandise. those compounds have already proven terrific therapeutic fee, particularly in oncology, infectious illnesses, pain control, infection, and neurological problems, underscoring the essential position of marine-derived molecules in addressing unmet clinical needs. the mixing of advanced technologies—which include genome mining, metabolomics, synthetic intelligence, and artificial biology—has fundamentally reshaped blue pharmacy from a largely exploratory enterprise into a systematic and facts-driven field. those tools allow the invention of cryptic biosynthetic pathways, boost up lead identification, and assist sustainable production strategies through microbial fermentation and heterologous expression. As a end result, the longstanding challenges of restrained compound deliver and ecological disruption are more and more being conquer, aligning drug improvement with marine conservation objectives. Sustainability lies on the center of blue pharmacy. The transition from extractive bioprospecting to cultivation-impartial procedures and biosynthetic engineering minimizes ecological stress on susceptible marine habitats even as making sure reproducible and scalable get right of entry to precious bioactive compounds. This conservation-driven version now not only preserves marine biodiversity however additionally strengthens the long-term viability of marine drug discovery pipelines. moreover, alignment with worldwide frameworks along with the conference on organic variety, the Nagoya Protocol, and the United countries Decade of Ocean technological know-how for Sustainable improvement reinforces moral research practices and equitable gain-sharing. Importantly, blue pharmacy contributes without delay to a couple of United countries Sustainable improvement dreams, which include right fitness and properly-being (SDG three), innovation and enterprise improvement (SDG nine), responsible production (SDG 12), and the conservation of marine ecosystems (SDG 14). by means of linking human fitness results with environmental stewardship, blue pharmacy exemplifies a included approach to sustainable improvement that transcends conventional disciplinary boundaries. in spite of its promise, blue pharmacy maintains to stand challenges associated with chemical complexity, regulatory pathways, weather change influences, and equitable get right of entry to to marine genetic resources. Addressing those barriers will require sustained investment in interdisciplinary research, supportive coverage frameworks, and worldwide collaboration. destiny progress will depend on the continued convergence of technological innovation, ecological consciousness, and moral governance. In end, blue pharmacy stands as a forward-searching and resilient version for pharmaceutical innovation inside the twenty-first century. by means of responsibly leveraging marine biodiversity and embracing sustainability at every stage of the drug discovery system, blue pharmacy has the capacity to deliver novel therapeutics even as safeguarding ocean fitness for destiny generations. persevered medical investment, coverage assist, and worldwide cooperation might be crucial to absolutely realise its promise for each worldwide fitness and marine conservation.

References

Blunt, J. W., Carroll, A. R., Copp, B. R., Davis, R. A., Keyzers, R. A., & Prinsep, M. R. (2018). Marine natural products. Natural Product Reports, 35(1), 8–53.

Blunt, J. W., Carroll, A. R., Copp, B. R., Davis, R. A., Keyzers, R. A., & Prinsep, M. R. (2024). Marine natural products. Natural Product Reports.

Carroll, A. R., Copp, B. R., Davis, R. A., Keyzers, R. A., & Prinsep, M. R. (2021). Marine natural products. Natural Product Reports, 38, 362–413.

Fenical, W., & Jensen, P. R. (2006). Developing a new resource for drug discovery: Marine actinomycete bacteria. Nature Chemical Biology, 2, 666–673.

Fitton, J. H., et al. (2021). Fucoidan and immune modulation. Marine Drugs, 19(9), 460.

Gerwick, W. H., & Moore, B. S. (2012). Lessons from the past and charting the future of marine natural products drug discovery. Chemical Biology, 19, 85–98.

Harden-Davies, H., et al. (2022). Marine genetic resources and benefit sharing. Nature Sustainability, 5, 930–938.

Holdt, S. L., & Kraan, S. (2011). Bioactive compounds in seaweed. Journal of Applied Phycology, 23, 543–597.

Leal, M. C., et al. (2020). Marine microorganism-derived bioactive compounds. Marine Drugs, 18(5), 236.

Leal, M. C., Puga, J., Serôdio, J., Gomes, N. C. M., & Calado, R. (2021). Trends in the discovery of new marine natural products from invertebrates over the last two decades. Marine Drugs, 19(9), 469.

Leal, M. C., Sheridan, C., Osinga, R., Dionísio, G., Rocha, R. J. M., Silva, B., & Calado, R. (2020). Marine microorganism-derived bioactive compounds. Marine Drugs, 18(5), 236.

Mayer, A. M. S., et al. (2010). Marine pharmacology. Biochimica et Biophysica Acta, 1790, 283–308.

Mayer, A. M. S., Rodríguez, A. D., Taglialatela-Scafati, O., & Fusetani, N. (2010). Marine pharmacology in 2007–8: Marine compounds with antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities. Biochimica et Biophysica Acta, 1790(5), 283–308.

Mehbub, M. F., Lei, J., Franco, C., & Zhang, W. (2014). Marine sponge-derived natural products. Marine Drugs, 12, 4539–4577.

Newman, D. J., & Cragg, G. M. (2020). Natural products as sources of new drugs. Journal of Natural Products, 83, 770–803.

Pan, C., et al. (2024). Marine fungi as a source of antibiotics. Frontiers in Marine Science, 11, 1538136.

Pan, C., Hassan, S. S. U., Muhammad, I., & Jin, H. (2024). Marine fungi as a source of novel antibiotics. Frontiers in Marine Science, 11, 1538136.

Pangestuti, R., & Kim, S. K. (2020). Bioactive compounds from marine algae. Marine Drugs, 18(7), 323.

Pangestuti, R., & Kim, S.-K. (2020). Bioactive compounds from marine algae. Marine Drugs, 18(5), 251

Romano, S., et al. (2019). One strain many compounds. Marine Drugs, 17(2), 124.

Shi, T., et al. (2024). Marine microorganism-derived natural products. Frontiers in Marine Science, 11.

Romano, S., Jackson, S. A., Patry, S., & Dobson, A. D. W. (2019). Extending the “one strain many compounds” principle. Marine Drugs, 17(2), 124.

Shannon, E., & Abu-Ghannam, N. (2019). Antibacterial derivatives of marine algae. Marine Drugs, 17(7), 414.

Shi, T., Wang, B., Zhao, D. L., & Newman, D. J. (2024). Marine microorganism-derived natural products. Frontiers in Marine Science, 11.

Shi, T., Wang, B., Zhao, D. L., & Newman, D. J. (2024). Marine microorganism-derived natural products. Frontiers in Marine Science, 11.

Stokes, J. M., et al. (2020). A deep learning approach to antibiotic discovery. Cell, 180, 688–702.

Stokes, J. M., et al. (2020). Deep learning approach to antibiotic discovery. Cell, 180, 688–702.

Taylor, M. W., Radax, R., Steger, D., & Wagner, M. (2007). Sponge-associated microorganisms. Microbiology and Molecular Biology Reviews, 71, 295–347.

Trindade, M., et al. (2021). Targeted metagenomics. Marine Drugs, 19(6), 307.

Trindade, M., van Zyl, L. J., Navarro-Fernández, J., & Abd Elrazak, A. (2021). Targeted metagenomics as a tool to tap into marine natural product diversity. Marine Drugs, 19(6), 307.

Trindade, M., van Zyl, L. J., Navarro-Fernández, J., & Abd Elrazak, A. (2021). Targeted metagenomics in marine drug discovery. Marine Drugs, 19(6), 307.

UN Ocean Decade. (2021). The United Nations Decade of Ocean Science for Sustainable Development (2021–2030). United Nations.

UNESCO. (2021). United Nations Decade of Ocean Science for Sustainable Development.

Wang, M., et al. (2016). Sharing and community curation of mass spectrometry data. Nature Biotechnology, 34, 828–837.

Zhang, Q., et al. (2024). Advances in marine natural product discovery and drug development. Journal of Ocean University of China, 23, 1297–1318.

Ziemert, N., Alanjary, M., & Weber, T. (2016). Genome mining for natural products. Nature Product Reports, 33, 988–1005.

Ziemert, N., et al. (2016). Genome mining. Natural Product Reports, 33, 988–1005.